Table 1.

Characteristics of the cohort (n = 259 patients/n = 41 patients).

	CD patients [(n = 259)/(n = 41)]
Age (mean ± SD)	41 ± 15/45 ± 15
Female sex (%)	145 (56%)/20 (49%)
Smoking (%)	43 (25%)/9 (22%)
Gastrointestinal surgery	54 (21%)/14 (34%)
Montreal A (%)	A1: 35 (19%)/4 (10%); A2: 124 (68%)/30 (77%); A3: 23 (13%)/5 (13%)
Montreal B (%)	B1: 111 (62%)/23 (61%); B2: 39 (22%)/10 (26%); B3: 29 (16%)/5 (13%)
Montreal L (%)	L1: 54 (29%)/10 (25%); L2: 31(17%)/7 (18%); L3: 99(54%)/23 (57%)
Fecal calprotectin (μg/g), median (IQR)	122.5 (31.75–529.75)/322 (72–531.5)
Anti-TNF (%)	154 (59%)/34 (83%)
Thiopurines (%)	126 (48%)/28 (68%)
MTX (%)	141 (54%)/8 (20%)

Montreal A (age at diagnosis): A1: < 16 years; A2: 17–40 years; and A3: > 40 years.

Montreal L (disease location): L1 ileum; L2 colon; L3 ileum–colon.

Montreal B (disease behavior): B1 inflammatory; B2 structuring; B3 penetrating.

Anti-TNF: infliximab, adalimumab, ustekinumab, vedolizumab.

Thiopurines: azathioprine, 6-mercaptopurine.

CD Crohn’s disease, MTX methotrexate.